View all available purchase options and get full access to this article. Supported by the National Institutes of Health T32 CA009599 and The University of Texas MD Anderson Cancer Center support grant ...

Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery Approximately 30% to 40% patients with a superficial ...

View all available purchase options and get full access to this article. Supported in part by the National Institute of Health (NIH), National Institute on Aging (NIA), Beeson Career Development Award ...

Randomized Controlled Trial of Family Therapy in Advanced Cancer Continued Into Bereavement To review the use of patient-reported outcome (PRO) data in medical product labeling granted by the US Food ...

View all available purchase options and get full access to this article.

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor–Induced Musculoskeletal Pain: SWOG S0927 We randomly assigned patients who were scheduled ...

Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes Although all authors completed the disclosure declaration, the following author(s) indicated a ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer Although all authors completed the ...

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial We examined patterns and predictors of LRR as first ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...